Agonist replacement therapy for cocaine dependence: A translational review

Future Medicinal Chemistry

Volumn 4, Issue 2, 2012, Pages 245-265

  Rush, Craig R ^a,b   Stoops, William W ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Use of a medication with similar effects to those of a drug of abuse to manage or treat drug dependence. Examples include methadone for opioid use or nicotine patches gum for smoking

Indexed keywords

AMPHETAMINE DERIVATIVE; BENZOYLECGONINE; COCAINE; DEXAMPHETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MONOAMINE DERIVATIVE;

ATTENTION DEFICIT DISORDER; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; COGNITIVE THERAPY; DAYTIME SOMNOLENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SELF ADMINISTRATION; HUMAN; INFORMATION RETRIEVAL; LABORATORY TEST; NARCOLEPSY; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH;

COCAINE-RELATED DISORDERS; HUMANS;

EID: 84856897821     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.184     Document Type: Review

References (176)

1. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, Rockville, MD, USA (2009).
2. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS) Highlights - 2007 National Admissions to Substance Abuse Treatment Services. Office of Applied Studies, Rockville, MD, USA (2009).
3. European Monitoring Centre for Drugs and Drug Addiction. 2009 Annual report on the state of the drugs problem in Europe. Publications Office of the European Union, Luxembourg (2009).
4. Chen K, Scheier LM, Kandel DB. Effects of chronic cocaine use on physical health: a prospective study in a general population sample. Drug Alcohol Depend. 43, 23-37 (1996). (Pubitemid 26382196)
5. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation 122, 2558-2569 (2010).
6. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: National Findings. Office of Applied Studies: Rockville, MD, USA (2010).
7. Rounsaville BJ, Anton SF, Carroll K, Budde D, Prusoff BA, Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch. Gen. Psychiatry 48, 43-51 (1991).
8. Van Tieu H, Koblin BA. HIV, alcohol and noninjection drug use. Curr. Opin HIV AIDS 4, 314-318 (2009).
9. Covi L, Hess JM, Schroeder JR, Preston KL. A dose response study of cognitive behavioral therapy in cocaine abusers. J. Subst. Abuse Treat. 23, 191-197 (2002). (Pubitemid 35254161)
10. McKee SA, Carroll KM, Sinha R et al. Enhancing brief cognitive-behavioral therapy with motivational enhancement techniques in cocaine users. Drug Alcohol Depend. 91(1), 97-101 (2007). (Pubitemid 47385030)
11. Higgins ST, Heil SH, Lussier JP. Clinical implications of reinforcement as a determinant of substance use disorders. Ann. Rev. Psychol. 55, 431-461 (2004).
12. Vocci FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr. Opin Psychiatry 22(3), 263-268 (2009).
13. de Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M. Pharmacological treatment of cocaine dependence: a systematic review. Addiction 97(8), 931-949 (2002).
14. Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr. Opin Psychiatry 18, 265-270 (2005). (Pubitemid 40586109)
15. Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs 64, 1547-1573 (2004). (Pubitemid 38981839)
16. Platt DM, Rowlett JK, Spealman RD. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 163, 265-282 (2002).
17. Cornish JW, Metzger D, Woody GE et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J. Subst. Abuse Treat. 14(6), 529-534 (1997). (Pubitemid 28053042)
18. Rea F, Bell JR, Young MR, Mattick RP. A randomized, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend. 75, 79-88 (2004). (Pubitemid 38844579)
19. Rose JE, Behm FM. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob. Res. 6, 523-532 (2004). (Pubitemid 38967541)
20. Grabowski J, Rhoades H, Stotts A et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 29, 969-981 (2004). (Pubitemid 38526797)
21. Karila L, Raynaud M, Aubin HJ et al. Pharmacological treatments for cocaine dependence: is there something new? Curr. Pharm. Des. 17(14), 1359-1368 (2011).
22. Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res. 102, 227-233 (2001). (Pubitemid 32607561)
23. Grabowski J, Rhoades H, Silverman P et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J. Clin. Psychopharmacol. 20, 305-310 (2000). (Pubitemid 30318358)
24. Kampman KM, Pettinati H, Lynch KG, Sparkman T, O'Brien CP. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 70, 265-273 (2003). (Pubitemid 36577338)
25. Grabowski J, Shearer J, Merrill J, Negus SS. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. 29, 1439-1464 (2004). (Pubitemid 39172183)
26. Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, Grabowski J. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 101(1-2), 34-41, (2009).
27. Henningfield JE. Nicotine medications for smoking cessation. N. Engl. J. Med. 333, 1196-1203 (1995).
28. Ling W, Rawson RA, Compton MA. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J. Psychoactive Drugs 26, 119-128 (1994). (Pubitemid 24218150)
29. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. CD000146 (2004).
30. Sofuoglu M, Kosten TR. Pharmacologic management of relapse prevention in addictive disorders. Psychiatr. Clin. North. Am. 27, 627-648 (2004). (Pubitemid 39535120)
31. Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion and triazolam in d-amphetamine-trained humans. Exp. Clin. Psychopharmacol. 6, 32-44 (1998). (Pubitemid 28102884)
32. Stoops WW, Glaser PE, Fillmore MT, Rush CR. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J. Psychopharmacol. 18, 534-543 (2004). (Pubitemid 39665121)
33. Negus SS. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine and methadone. J. Pharmacol. Exp. Ther. 317, 711-723 (2006).
34. Negus SS, Rice KC. Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys. Neuropsychopharmacology 34, 899-911 (2009).
35. Czoty PW, Martelle JL, Nader MA. Influence of abstinence and conditions of cocaine access on the reinforcing strength of cocaine in nonhuman primates. Drug Alcohol Depend. 85, 213-220 (2006). (Pubitemid 44666278)
36. Banks ML, Negus SS. Effects of extended cocaine access and cocaine withdrawal on choice between cocaine and food in rhesus monkeys. Neuropsychopharmacology 35, 493-504 (2010).
37. Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 406, 1-13 (2000).
38. Johanson CE, Fischman MW. The pharmacology of cocaine related to its abuse. Pharmacol. Rev. 41, 3-52 (1989). (Pubitemid 19247826)
39. Rothman RB, Glowa JR. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development: focus on GBR 12909. Mol. Neurobiol. 11, 1-19 (1995).
40. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237(4819), 1219-1223 (1987). (Pubitemid 17131228)
41. Rothman RB, Baumann MH, Dersch CM et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32-41 (2001).
42. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 14(7), 299-302 (1991).
43. Witkin JM. Pharmacotherapy of cocaine abuse: preclinical development. Neurosci. Biobehav. Rev. 18, 121-142 (1994). (Pubitemid 24058930)
44. Woolverton WL, Johnson KM. Neurobiology of cocaine abuse. Trends Pharmacol. Sci. 13, 193-200 (1992).
45. Holmes VF. Medical use of psychostimulants: an overview. Int. J. Psychiatry Med. 25(1), 1-19 (1995).
46. Wilens TE, Biederman J, Spencer TJ, Prince J. Pharmacotherapy of adult attention/deficit hyperactivity disorder: a review. J. Clin. Psychopharmacol. 15(4), 270-279 (1995).
47. Gatley SJ, Volkow ND, Gifford AN et al. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology 146(1), 93-100 (1999). (Pubitemid 29441119)
48. Volkow ND, Fowler JS, Gatley JS et al. Comparable changes in synaptic dopamine induced by methylphenidate and cocaine in the baboon brain. Synapse 31, 59-66 (1999). (Pubitemid 29009280)
49. Volkow ND, Wang GJ, Fowler JS et al. Methylphenidate and cocaine have similar in vivo potency to block the dopamine transporters in the human brain. Life Sci. 65, 7-12 (1999).
50. Volkow ND, Ding YS, Fowler JS et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry 52, 456-463 (1995).
51. Bergman J, Madras BK, Johnson SE, Spealman RD. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J. Pharmacol. Exp. Ther. 251(1), 150-155 (1989). (Pubitemid 19261957)
52. Greenwald MK, Lundahl LH, Steinmiller CL. Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/ heroin polydrug abusers. Neuropsychopharmacology 35(13), 2624-2637 (2010).
53. Stoops WW, Glaser PE, Rush CR. Reinforcing, subject-rated, and physiological effects of intranasal methylphenidate in humans: a dose-response analysis. Drug Alcohol Depend. 71, 179-186 (2003). (Pubitemid 37289027)
54. Rush CR, Baker RW. Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp. Clin. Psychopharmacol. 9(1), 59-73 (2001). (Pubitemid 32852215)
55. Wood DM, Emmett-Oglesby MW. Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine. Psychopharmacology 95, 364-368 (1988).
56. Fischman MW, Foltin RW. Cocaine self-administration research: implications for rational pharmacotherapy. In: Cocaine Abuse Research: Pharmacology, Behavior and Clinical Applications. Higgins ST, Katz JL (Eds). Academic Press, San Diego, CA, USA, 181-208 (1998).
57. Bigelow GE, Walsh SL. Evaluation of potential pharmacotherapies: response to cocaine challenge in the human laboratory. In: Cocaine Abuse Research: Pharmacology, Behavior and Clinical Applications. Higgins ST, Katz JL (Eds). Academic Press, San Diego, CA, USA, 209-238 (1998).
58. Glowa JR, Fantegrossi WE. Effects of dopaminergic drugs on food- and cocaine-maintained responding. IV: Continuous cocaine infusions. Drug Alcohol Depend. 45, 71-79 (1997). (Pubitemid 27246408)
59. Hiranita T, Soto PL, Newman AH, Katz JL. Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J. Pharmacol. Exp. Ther. 329(2), 677-686 (2009).
60. Negus SS. Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. Neuropsychopharmacology 28, 919-931 (2003).
61. Skjoldager P, Winger G, Woods JH. Effects of GBR 12909 and cocaine on cocaine-maintained behavior in rhesus monkeys. Drug Alcohol Depend. 33, 31-39 (1993). (Pubitemid 23219907)
62. Collins SL, Levin FR, Foltin RW, Kleber HD, Evans SM. Response to cocaine alone and in combination with methylphenidate in cocaine abusers with ADHD. Drug Alcohol Depend. 82, 158-167 (2006).
63. Walsh SL, Haberny KA, Bigelow GE. Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology 150, 361-373 (2000). (Pubitemid 30470214)
64. Winhusen T, Somoza E, Singal BM et al. Methylphenidate and cocaine: a placebo-controlled drug interaction study. Pharmacol. Biochem. Behav. 85, 29-38 (2006). (Pubitemid 44772906)
65. Oliveto AH, Rosen MI, Woods SW, Kosten TR. Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans. J. Pharmacol. Exp. Ther. 272, 231-241 (1995).
66. Van Dyke C, Jatlow P, Ungerer J, Barash PG, Byck R. Oral cocaine: plasma concentrations and central effects. Science 200, 211-213 (1978). (Pubitemid 8310535)
67. Johanson CE, Lundahl LH, Schubiner H. Effects of oral cocaine on intravenous cocaine discrimination in humans. Exp. Clin. Psychopharmacol. 15(3), 219-227 (2007). (Pubitemid 47445250)
68. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence: methylphenidate. J. Clin. Psychopharmacol. 17(6), 485-488 (1997). (Pubitemid 28389189)
69. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 87(1), 20-29 (2007). (Pubitemid 46074379)
70. Schubiner H, Saules KK, Arfken CL et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp. Clin. Psychopharmacol. 10(3), 286-294 (2002). (Pubitemid 34919937)
71. Fischman MW, Johanson CE. Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers. Behav. Pharmacol. 9, 479-498 (1998). (Pubitemid 28552540)
72. Perkins KA, Lerman C, Stitzer M et al. Development of procedures for early screening of smoking cessation medications in humans. Clin. Pharmacol. Ther. 84, 216-221 (2008).
73. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Ann. Rev. Pharmacol. Toxicol. 33, 639-677 (1993). (Pubitemid 23116021)
74. Carroll ME, Lac ST. Acquisition of i.v. amphetamine and cocaine self-administration in rats as a function of dose. Psychopharmacology 129, 206-214 (1997). (Pubitemid 27085390)
75. Gasior M, Bergman J, Kallman MJ, Paronis CA. Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacology 30, 758-764 (2005).
76. Richardson NR, Roberts DCS. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J. Neurosci. Methods 66, 1-11 (1996). (Pubitemid 26180064)
77. Shannon HE, Risner ME. Comparison of behavior maintained by intravenous cocaine and d-amphetamine in dogs. J. Pharmacol. Exp. Ther. 229, 422-432 (1984). (Pubitemid 14149031)
78. Woolverton WL, Hecht GS, Agoston GE, Katz JL, Newman AH. Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys. Psychopharmacology 154, 375-382 (2001). (Pubitemid 32260896)
79. Hodos W. Progressive ratio as a measure of reward strength. Science 134, 943-944 (1961).
80. Johanson CE, Lundahl LH, Lockhart N, Schubiner H. Intravenous cocaine discrimination in humans. Exp. Clin. Psychopharmacol. 14(2), 99-108 (2006). (Pubitemid 43988628)
81. Kamien JB, Woolverton WL. A pharmacological analysis of the discriminative stimulus properties of d-amphetamine in rhesus monkeys. J. Pharmacol. Exp. Ther. 248, 938-946 (1989). (Pubitemid 19100738)
82. Li SM, Campbell BL, Katz JL. Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. J. Pharmacol. Exp. Ther. 317(3), 1088-1096 (2006). (Pubitemid 43764112)
83. Oliveto AH, McCance-Katz E, Singha A, Hameedi F, Kosten TR. Effects of d-amphetamine and caffeine in humans under a cocaine discrimination procedure. Behav. Pharmacol. 9, 207-217 (1998). (Pubitemid 28273108)
84. Barrett AC, Miller JR, Dohrmann JM, Caine SB. Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropharmacology 47(Suppl. 1), 256-273 (2004). (Pubitemid 39298269)
85. Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le Moal M, Piazza PV. Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology 161(4), 387-395 (2002). (Pubitemid 34595790)
86. Chiodo KA, Roberts DC. Decreased reinforcing effects of cocaine following 2 weeks of continuous d-amphetamine treatment in rats. Psychopharmacology 206, 447-456 (2009).
87. Chiodo KA, Lack CM, Roberts DC. Cocaine self-administration reinforced on a progressive ratio schedule decreases with continuous d-amphetamine treatment in rats. Psychopharmacology 200, 465-473 (2008).
88. Czoty PW, Martelle JL, Carroll FI, Nader MA. Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates. Pharmacol. Biochem. Behav. 96(3), 274-278 (2010).
89. Czoty PW, Gould RW, Martelle JL, Nader MA. Prolonged attenuation of the reinforcing strength of cocaine by chronic d-amphetamine in rhesus monkeys. Neuropsychopharmacology 36(2), 539-547 (2011).
90. Negus SS, Mello NK. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology 167, 324-332 (2003a). (Pubitemid 36712980)
91. Negus SS, Mello NK. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend. 70, 39-52 (2003b). (Pubitemid 36385152)
92. Negus SS, Mello NK, Blough BE, Baumann MH, Rothman RB. Monoamine releasers with varying selectivity for dopamine/ norepinephrine versus serotonin release as candidate 'agonist' medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J. Pharmacol. Exp. Ther. 320, 627-636 (2007). (Pubitemid 46147942)
93. Rush CR, Stoops WW, Sevak RJ, Hays LR. Cocaine choice in humans during d-amphetamine maintenance. J. Clin. Psychopharmacol. 30(2), 152-159 (2010).
94. Rush CR, Stoops WW, Hays LR. Cocaine effects during d-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend. 99, 261-271 (2009).
95. Griffiths RR, Troisi JR, Silverman K, Mumford GK. Multiple-choice procedure: an efficient approach for investigating drugreinforcement in humans. Behav. Pharmacol. 4(1), 3-13 (1993). (Pubitemid 23062644)
96. Griffiths RR, Rush CR, Puhala KA. Validation of the multiple-choice procedure for investigating drug reinforcement in humans. Exp. Clin. Psychopharmacol. 4, 97-106 (1996). (Pubitemid 26077300)
97. Grabowski J, Rhoades H, Schmitz J et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 21(5), 522-526 (2001). (Pubitemid 32937435)
98. Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 98, 1137-1141 (2003). (Pubitemid 36936500)
99. Higgins ST, Delaney DD, Budney AJ et al. A behavioral approach to achieving initial cocaine abstinence. Am. J. Psychiatry 148(9), 1218-1224 (1991).
100. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann. Pharmacother. 35(12), 1608-1613 (2001). (Pubitemid 34027464)
101. Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int. J. Chron. Obstruct. Pulmon. Dis. 3, 45-53 (2008). (Pubitemid 351523717)
102. Bredeloux P, Dubuc I, Costentin J. Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br. J. Pharmacol. 150, 711-719 (2007). (Pubitemid 46440220)
103. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 2(4), 273-279 (1989). (Pubitemid 20025254)
104. Kleven MS, Anthony EW, Woolverton WL. Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 254(1), 312-317 (1990). (Pubitemid 20262058)
105. Griffith JD, Carranza J, Griffith C, Miller LL. Bupropion: clinical assay for amphetamine-like abuse potential. J. Clin. Psychiatry 44(5 Pt 2), 206-208 (1983). (Pubitemid 13088868)
106. Miller L, Griffith J. A comparison of bupropion, dextroamphetamine and placebo in mixed-substance abusers. Psychopharmacology 80(3), 199-205 (1983). (Pubitemid 13078832)
107. Peck AW, Bye CE, Clubley M, Henson T, Riddington C. A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects. Br. J. Clin. Pharmacol. 7(5), 469-478 (1979). (Pubitemid 9181193)
108. Oliveto A, McCance-Katz FE, Singha A, Petrakis I, Hameedi F, Kosten TR. Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. Drug Alcohol Depend. 63(2), 155-167 (2001). (Pubitemid 32488930)
109. Stoops WW, Lile JA, Hays LR, Glaser PE, Rush CR. Influence of acute bupropion pretreatment on the effects of intranasal cocaine. Addiction (2012) (In press).
110. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 81(2), 137-148 (2006). (Pubitemid 41821797)
111. Margolin A, Kosten T, Petrakis I, Avants SK. Bupropion reduces cocaine abuse in methadone-maintained patients. Arch. Gen. Psychiatry 48(1), 87 (1991).
112. Margolin A, Kosten TR, Avants SK et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 40(2), 125-131 (1995). (Pubitemid 26011975)
113. Poling J, Oliveto A, Petry N et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch. Gen. Psychiatry 63(2), 219-228 (2006). (Pubitemid 43213884)
114. Shoptaw S, Heinzerling KG, Rotheram-Fuller E et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J. Addict. Dis. 27, 13-23 (2008).
115. Broughton RJ, Fleming JA, George CF et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 49, 444-451 (1997). (Pubitemid 27368880)
116. Miller JL. Modafinil approved for narcolepsy. Am. J. Health Syst. Pharm. 56(4), 304 (1999).
117. Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med. 1, 109-116 (2000).
118. Teitelman E. Modafinil for narcolepsy. Am. J. Psychiatry 158, 970-971 (2001).
119. Andersen ML, Kessler E, Murnane KS, McClung JC, Tufik S, Howell LL. Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology 210(3), 439-448 (2010).
120. Madras BK, Xie Z, Lin Z et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J. Pharmacol. Exp. Ther. 319(2), 561-569 (2006).
121. Volkow ND, Fowler JS, Logan J et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301, 1148-1154 (2009).
122. Zolkowska D, Jain R, Rothman RB et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J. Pharmacol. Exp. Ther. 329, 738-746 (2009).
123. Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur. J. Pharmacol. 568(1-3), 112-123 (2007). (Pubitemid 46976895)
124. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology 126(4), 286-292 (1996). (Pubitemid 26276699)
125. Newman JL, Negus SS, Lozama A, Prisinzano TE, Mello NK. Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Exp. Clin. Psychopharmacol. 18(5), 395-408 (2010).
126. Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioral and physiological effects of modafinil in drug abusers. Behav. Pharmacol. 13(2), 105-115 (2002). (Pubitemid 34450696)
127. Rush CR, Kelly TH, Hays LR, Wooten AF. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend. 67(3), 311-322 (2002a). (Pubitemid 34786266)
128. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J. Psychopharmacol. 14(1), 53-60 (2000). (Pubitemid 30156539)
129. Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin. Neuropharmacol. 23(3),149-156 (2000). (Pubitemid 30395376)
130. Malcolm R, Book SW, Moak D, DeVane L, Czepowicz V. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am. J. Addict. 11, 247-249 (2002). (Pubitemid 34856441)
131. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical and post-marketing surveillance - a review of abuse liability issues. Ann. Clin. Psychiatry 16(2), 101-109 (2004). (Pubitemid 39089110)
132. Vosburg SK, Hart CL, Haney M, Rubin E, Foltin RW. Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend. 106, 233-236 (2010).
133. Dackis CA, Lynch KG, Yu E et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 70(1), 29-37 (2003). (Pubitemid 36385151)
134. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33(4), 761-768 (2008). (Pubitemid 351252706)
135. Malcolm R, Swayngim K, Donovan JL et al. Modafinil and cocaine interactions. Am. J. Drug Alcohol Abuse 32(4), 577-587 (2006). (Pubitemid 44870996)
136. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30(1), 205-211 (2005). (Pubitemid 40024415)
137. Anderson AL, Reid MS, Li SH et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 104(1-2), 133-139 (2009).
138. Carroll FI, Howell LL, Kuhar MJ. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem. 42, 2721-2736 (1999). (Pubitemid 29370417)
139. Carroll FI, Pawlush N, Kuhar MJ, Pollard GT, Howard JL. Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3b-(substituted phenyl)-2b-(′-substituted isoxazol-5-yl) tropanes. J. Med. Chem. 47, 296-302 (2004). (Pubitemid 38057875)
140. Carroll FI, Runyon SP, Abraham P et al. Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted- phenyl)tropane-2-carboxylic acid methyl ester isomers. J. Med. Chem. 47, 6401-6409 (2004). (Pubitemid 39587263)
141. Carroll FI, Howard JL, Howell LL, Fox BS, Kuhar MJ. Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS J. 8, E196-E203 (2006).
142. Carroll FI, Fox BS, Kuhar MJ, Howard JL, Pollard GT, Schenk S. Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration. Eur. J. Pharmacol. 553, 149-156 (2006). (Pubitemid 44779595)
143. Kimmel HL, O'Connor JA, Carroll FI, Howell LL. Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol. Biochem. Behav. 86(1), 45-54 (2007). (Pubitemid 46274968)
144. Kimmel HL, Negus SS, Wilcox KM et al. Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol. Biochem. Behav. 90(3), 453-462 (2008).
145. Howell LL, Carroll FI, Votaw JR, Goodman MM, Kimmel HL. Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J. Pharmacol. Exp. Ther. 320(2), 757-765 (2007). (Pubitemid 46147957)
146. Haile CN, Zhang XY, Carroll FI, Kosten TA. Cocaine self-administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine transporter. Brain Res. 1055(1-2), 186-195 (2005). (Pubitemid 41224244)
147. Czoty PW, Ginsburg BC, Howell LL. Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J. Pharmacol. Exp. Ther. 300(3), 831-837 (2002). (Pubitemid 34164986)
148. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J. Pharmacol. Exp. Ther. 313, 848-854 (2005). (Pubitemid 40604187)
149. Rothman RB, Blough BE, Woolverton WL et al. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J. Pharmacol. Exp. Ther. 313, 1361-1369 (2005). (Pubitemid 40727043)
150. Negus SS, Baumann MH, Rothman RB, Mello NK, Blough BE. Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+) phenmetrazine, and 4-benzylpiperidine. J. Pharmacol. Exp. Ther. 329, 272-281 (2009).
151. Abreu ME, Bigelow GE, Fleisher L, Walsh SL. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology 154(1), 76-84 (2001). (Pubitemid 32186518)
152. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp. Clin. Psychopharmacol. 6(4), 367-374 (1998). (Pubitemid 29001514)
153. Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, Phase I study in healthy adult volunteers. Clin. Drug. Investig. 28, 745-755 (2008).
154. Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr. Med. Res. Opin 24, 33-40 (2008). (Pubitemid 351160236)
155. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J. Psychopharmacol. 23, 410-418 (2009).
156. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J.
157. Rothman RB, Dersch CM, Carroll FI, Ananthan S. Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding. Synapse 43, 268-274 (2002). (Pubitemid 34118264)
158. de la Garza R, Johanson CE. Discriminative stimulus properties of intragastrically administered d-amphetamine and pentobarbital in rhesus monkeys. J. Pharmacol. Exp. Ther. 243(3), 955-962 (1987). (Pubitemid 18017148)
159. Evans SM, Johanson CE. Amphetamine-like effects of anorectics and related compounds in pigeons. J. Pharmacol. Exp. Ther. 241, 817-825 (1987).
160. Corwin RL, Woolverton WL, Schuster CR, Johanson CE. Anorectics: effects on food intake and self-administration in rhesus monkeys. Alcohol Drug Res. 7, 351-361 (1987). (Pubitemid 17113752)
161. Griffiths RR, Brady JV, Bradford LD. Predicting the abuse liability of drugs with animal drug self-administration procedures: psychomotor stimulants and hallucinogens. In: Advances in Behavioral Pharmacology, Volume 2. Thompson T, Dews PB (Eds). Academic Press, NY, USA 163-208 (1979).
162. Bramble D. Psychostimulants and psychiatrists: the Trent Adult Psychiatry Psychostimulant Survey. J. Psychopharmacol. 14, 67-69 (2000). (Pubitemid 30156541)
163. Klein RG. The role of methylphenidate in psychiatry. Arch. Gen. Psychiatry 52, 429-433 (1995).
164. Goeders NE, McNulty MA, Mirkis S, McAllister KH. Chlordiazepoxide alters intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav. 33, 859-866 (1989). (Pubitemid 19284301)
165. Goeders NE, McNulty MA, Guerin GF. Effects of alprazolam on intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav. 44, 471-474 (1993).
166. Goeders NE, Guerin GF. Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol. Biochem. Behav. 91, 181-189 (2008).
167. Goeders NE, Clampitt DM. Potential role for the hypothalamo-pituitary- adrenal axis in the conditioned reinforcer-induced reinstatement of extinguished cocaine seeking in rats. Psychopharmacology 161, 222-232 (2002). (Pubitemid 34591660)
168. Keim KL, Sigg EB. Plasma corticosterone and brain catecholamines in stress: effect of psychotropic drugs. Pharmacol. Biochem. Behav. 6, 79-85 (1977). (Pubitemid 8079131)
169. Yang XM, Gorman AL, Dunn AJ, Goeders, NE. Anxiogenic effects of acute and chronic cocaine administration: neurochemical and behavioral studies. Pharmacol. Biochem. Behav. 41, 643-650 (1992).
170. Goeders NE, Guerin GF. Effects of surgical and pharmacological adrenalectomy on the initiation and maintenance of intravenous cocaine self-administration in rats. Brain Res. 722, 145-152 (1996). (Pubitemid 26199364)
171. Lile JA, Stoops WW, Glaser PEA, Hays LR, Rush CR. Subjective and physiological effects of acute intranasal methamphetamine during extended-release alprazolam maintenance. Drug Alcohol Depend. 119(3), 187-193 (2011).
172. Mumford GK, Evans SM, Fleishaker, JC, Griffiths, RR. Alprazolam absorption kinetics affects abuse liability. Clin. Pharmacol. Ther. 57, 356-365 (1995).
173. Mumford GK, Rush CR, Griffiths, RR. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J. Pharmacol. Exp. Ther. 272, 570-580 (1995).
174. Rush CR, Griffiths RR. Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Exp. Clin. Psychopharmacol. 5, 28-38 (1997). (Pubitemid 27087315)
175. Rush CR, Higgins ST, Bickel WK, Hughes JR. Abuse liability of alprazolam relative to other commonly used benzodiazepines: a review. Neurosci. Biobehav. Rev. 17, 277-285 (1993). (Pubitemid 23306315)
176. Kablinger AS, Lindner MA, Casso S et al. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study. J. Psychopharmacol. (2011) (In Press).